All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.

What about risks? Every company has them, and we've spotted 5 warning signs for Medigene (of which 2 are concerning!) you should know about.